Unibest

Pharmaceutical intermediates

Gilteritinib Intermediates

2 pharmaceutical intermediates for Gilteritinib. Indication: Leukemia, Myeloid, Acute.

Submit a ProjectAll intermediates

About Gilteritinib

Originator
Astellas Pharma Inc.
Indication
Leukemia, Myeloid, Acute
Approved Date
11/28/2018
DS/DP
07/28/2030

Available intermediates

2 intermediates currently listed for Gilteritinib. Request specifications, documentation or a quotation for any item below.

Gilteritinib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
Methyl-4-(4-piperidyl)piperazineTrihydrochloride1621519-77-4//
1-(1-(2-methoxy-4-nitrophenyl)piperidin-4-yl)-4-methylpiperazine254058-33-7//

Other programs under G

GadobutrolGepotidacin

Building toward Gilteritinib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

Submit a Project Talk to the team

How can we help you?

Receive insights into the latest events and regulatory updates

Sent directly to your email

Get industry insights and Unibest news here

Contact Us →